In-vitro studies of a new oral azole antimycotic, BAY N 7133
- 1 February 1983
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 11 (2), 135-149
- https://doi.org/10.1093/jac/11.2.135
Abstract
The in-vitro antifungal activities of BAY N 7133, a new orally absorbed synthetic azole derivative against 364 strains of fungal pathogens were studied in direct comparison with another orally active azole compound ketoconazole, using an agar dilution procedure. BAY N 7133 was found to havea broad spectrum of antifunga] activity and to inhibit most pathogenic yeasts and fungi at concentrations ranging from ≤0.04 to 10 mg/1, with the exception only of some strains of zygomycetic pathogens. It was equal to or even greater than ketoconazole in activity against most of the fungal pathogens tested. Composition and pH of culture media and inoculum size altered the effect of BAY N 7133. No in-vitro development of drug resistance was demonstrated. BAY N 7133 can be considered to have a possible usefulness in the treatment of human mycoses.Keywords
This publication has 5 references indexed in Scilit:
- The activity in vitro and in vivo of a new imidazole antifungal, ketoconazoleJournal of Antimicrobial Chemotherapy, 1980
- Variability of Agar Dilution-Replicator Method of Yeast Susceptibility TestingAntimicrobial Agents and Chemotherapy, 1979
- Comparison of the in Vitro Antifungal Activities of Miconazole and a New Imidazole, R41,400The Journal of Infectious Diseases, 1978
- In vitro studies with miconazole and miconazole nitrateJournal of Antimicrobial Chemotherapy, 1977
- Effect of Culture Media on the Antifungal Activity of Miconazole and Amphotericin B Methyl EsterThe Journal of Infectious Diseases, 1976